ES2545853T3 - Derivados de pirrolotriazinona como inhibidores de PI3K - Google Patents

Derivados de pirrolotriazinona como inhibidores de PI3K Download PDF

Info

Publication number: ES2545853T3
Authority: ES; Spain
Prior art keywords: group; formula; linear; iiia; hydrogen atom
Prior art date: 2011-04-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES12717685.7T

Other languages

English (en)

Spanish (es)

Inventor

Francisco Javier Bernal Anchuela

Marta Carrascal Riera

Juan Francisco Caturla Javaloyes

Jordi Gracia Ferrer

Victor Giulio Matassa

Emma Terricabras Belart

Joan Taltavull Moll

Montserrat Erra Sola

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Almirall SA

Original Assignee

Almirall SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-29

Filing date

2012-04-26

Publication date

2015-09-16

2012-04-26 Application filed by Almirall SA filed Critical Almirall SA

2015-09-16 Application granted granted Critical

2015-09-16 Publication of ES2545853T3 publication Critical patent/ES2545853T3/es

Status Active legal-status Critical Current

2032-04-26 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

ES12717685.7T 2011-04-29 2012-04-26 Derivados de pirrolotriazinona como inhibidores de PI3K Active ES2545853T3 (es)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP11382124		2011-04-29
EP11382124A EP2518070A1 (fr)	2011-04-29	2011-04-29	Dérivés de pyrrolotriazinon en tant qu'inhibiteurs PI3K
US201161502550P	2011-06-29	2011-06-29
US201161502550P		2011-06-29
PCT/EP2012/057671 WO2012146666A1 (fr)	2011-04-29	2012-04-26	Dérivés de pyrrolotriazinone en tant qu'inhibiteurs de pi3k

Publications (1)

Publication Number	Publication Date
ES2545853T3 true ES2545853T3 (es)	2015-09-16

Family

ID=44484054

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES12717685.7T Active ES2545853T3 (es)	2011-04-29	2012-04-26	Derivados de pirrolotriazinona como inhibidores de PI3K

Country Status (36)

Country	Link
US (1)	US9340547B2 (fr)
EP (2)	EP2518070A1 (fr)
JP (1)	JP5903160B2 (fr)
KR (1)	KR20140021622A (fr)
CN (1)	CN103649089B (fr)
AR (1)	AR086144A1 (fr)
AU (1)	AU2012247491B2 (fr)
BR (1)	BR112013023876A2 (fr)
CA (1)	CA2826197A1 (fr)
CL (1)	CL2013003073A1 (fr)
CO (1)	CO6801747A2 (fr)
CR (1)	CR20130543A (fr)
CY (1)	CY1116871T1 (fr)
DK (1)	DK2702061T3 (fr)
EA (1)	EA024350B1 (fr)
ES (1)	ES2545853T3 (fr)
GT (1)	GT201300266A (fr)
HK (1)	HK1195552A1 (fr)
HR (1)	HRP20151153T1 (fr)
HU (1)	HUE026041T2 (fr)
IL (1)	IL227764A (fr)
ME (1)	ME02210B (fr)
MX (1)	MX336214B (fr)
MY (1)	MY171553A (fr)
PE (1)	PE20141193A1 (fr)
PL (1)	PL2702061T3 (fr)
PT (1)	PT2702061E (fr)
RS (1)	RS54270B1 (fr)
SG (1)	SG194084A1 (fr)
SI (1)	SI2702061T1 (fr)
SM (1)	SMT201500270B (fr)
TW (2)	TWI535720B (fr)
UA (1)	UA111197C2 (fr)
UY (1)	UY34051A (fr)
WO (1)	WO2012146666A1 (fr)
ZA (1)	ZA201305612B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2518070A1 (fr)	2011-04-29	2012-10-31	Almirall, S.A.	Dérivés de pyrrolotriazinon en tant qu'inhibiteurs PI3K
EP2790705B1 (fr)	2011-12-15	2017-12-06	Novartis AG	Utilisation d'inhibiteurs de l'activité ou de la fonction de pi3k
WO2014015523A1 (fr) *	2012-07-27	2014-01-30	Hutchison Medipharma Limited	Nouveaux composés hétéroaryliques et hétérocycliques et compositions et procédés s'y rapportant
AU2013333938A1 (en) *	2012-10-16	2015-04-09	Almirall, S.A.	Pyrrolotriazinone derivatives as PI3K inhibitors
CN104870017B (zh) *	2012-11-08	2020-08-14	理森制药股份公司	含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
WO2014075393A1 (fr) *	2012-11-16	2014-05-22	Merck Sharp & Dohme Corp.	Inhibiteurs puriques de la phosphatidylinositol 3-kinase delta humaine
WO2014082230A1 (fr) *	2012-11-28	2014-06-05	上海希迈医药科技有限公司	Dérivés de pyrrolo-triazine, leur procédé de préparation et leur application médicale
WO2014087208A2 (fr) *	2012-12-06	2014-06-12	Enaltec Labs Pvt. Ltd.	Procédé de préparation d'alcaftadine
CA2895782C (fr)	2012-12-21	2017-08-22	Gilead Calistoga Llc	Pyrimidine aminoalkyl-quinazolones substituees en tant qu'inhibiteurs de phosphatidylinositol 3-kinase
JP6207100B2 (ja) *	2012-12-21	2017-10-04	ギリアードカリストガエルエルシー	イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
AR094797A1 (es) *	2013-02-15	2015-08-26	Almirall Sa	Derivados de pirrolotriazina como inhibidores de pi3k
NZ714710A (en) *	2013-06-14	2016-11-25	Gilead Sciences Inc	Phosphatidylinositol 3-kinase inhibitors
JP6542216B2 (ja) *	2013-08-13	2019-07-10	ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア	デオキシシチジンキナーゼ阻害因子
GB201402431D0 (en)	2014-02-12	2014-03-26	Karus Therapeutics Ltd	Compounds
MX2020004398A (es) *	2014-04-08	2022-06-06	Incyte Corp	Tratamiento de neoplasias malignas de linfocitos b mediante una combinacion de inhibidores de janus cinasa (jak) y fosfatidilinositol 3 cinasa (pi3k).
MD20160137A2 (ro) *	2014-05-27	2017-05-31	Almirall S.A.	Utilizare medicală
AU2015274637B2 (en) *	2014-06-13	2018-04-19	Gilead Sciences, Inc.	Phosphatidylinositol 3-kinase inhibitors
ES2763104T3 (es)	2014-06-13	2020-05-27	Gilead Sciences Inc	Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-quinasa
EP3154960A1 (fr)	2014-06-13	2017-04-19	Gilead Sciences, Inc.	Inhibiteurs de la phosphatidylinositol 3-kinase
MA40250A (fr)	2014-07-04	2017-05-10	Lupin Ltd	Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
WO2016054491A1 (fr)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
WO2016066142A1 (fr)	2014-11-01	2016-05-06	Shanghai Fochon Pharmaceutical Co., Ltd.	Inhibiteurs de certaines protéines kinases
CN107207444B (zh)	2014-11-26	2020-07-24	武田药品工业株式会社	二环化合物
CN105712998B (zh) *	2014-12-05	2019-12-13	上海润诺生物科技有限公司	氮杂吲哚类衍生物、其制备方法及其在医药上的应用
GB201514758D0 (en)	2015-08-19	2015-09-30	Karus Therapeutics Ltd	Formulation
US20190099404A1 (en) *	2016-03-16	2019-04-04	Zeno Royalties & Milestones, LLC	Analgesic compounds
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3568395A1 (fr)	2017-01-10	2019-11-20	Bayer Aktiengesellschaft	Dérivés hétérocycliques utilisés comme pesticides
US11129818B2 (en)	2017-06-07	2021-09-28	Arcutis Biotherapeutics, Inc.	Topical roflumilast formulation having improved delivery and plasma half life
US9895359B1 (en)	2017-06-07	2018-02-20	Arcutis, Inc.	Inhibition of crystal growth of roflumilast
CN107383004B (zh) *	2017-07-05	2020-04-17	浙江大学	2-氨基咪唑并吡啶类衍生物及制备和应用
WO2019040499A2 (fr) *	2017-08-21	2019-02-28	Navigen, Inc.	Inhibiteurs d'arf6 et procédés associés
CN111212839A (zh) *	2017-09-15	2020-05-29	艾杜罗生物科技公司	吡唑并嘧啶酮化合物及其用途
US11534493B2 (en)	2017-09-22	2022-12-27	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
WO2020007698A1 (fr) *	2018-07-06	2020-01-09	Leo Pharma A/S	Nouveaux dérivés d'amino-imidazopyrimidine utilisés en tant qu'inhibiteurs de janus kinase et leur utilisation pharmaceutique
US20220289751A1 (en) *	2019-07-17	2022-09-15	Ono Pharmaceutical Co., Ltd.	Compound having kdm5 inhibitory activity and pharmaceutical use thereof
CN111346095B (zh) *	2020-03-14	2021-06-08	温州医科大学附属第二医院、温州医科大学附属育英儿童医院	用于治疗神经外科术后头痛的药物制剂
JP2023525383A (ja) *	2020-05-16	2023-06-15	フォチョン・バイオサイエンシーズ・リミテッド	キナーゼ阻害剤としての化合物
US20240108609A1 (en)	2022-09-15	2024-04-04	Arcutis Biotherapeutics, Inc.	Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT7920688V0 (it)	1979-02-05	1979-02-05	Chiesi Paolo Parma	Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
US5200416A (en) *	1980-05-12	1993-04-06	Usv Pharmaceutical Corporation	Cyclic amides
DE3274065D1 (de)	1981-07-08	1986-12-11	Draco Ab	Powder inhalator
US4570630A (en)	1983-08-03	1986-02-18	Miles Laboratories, Inc.	Medicament inhalation device
FI69963C (fi)	1984-10-04	1986-09-12	Orion Yhtymae Oy	Doseringsanordning
DE3927170A1 (de)	1989-08-17	1991-02-21	Boehringer Ingelheim Kg	Inhalator
IT1237118B (it)	1989-10-27	1993-05-18	Miat Spa	Inalatore multidose per farmaci in polvere.
US5201308A (en)	1990-02-14	1993-04-13	Newhouse Michael T	Powder inhaler
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
SG45171A1 (en)	1990-03-21	1998-01-16	Boehringer Ingelheim Int	Atomising devices and methods
GB9015522D0 (en)	1990-07-13	1990-08-29	Braithwaite Philip W	Inhaler
WO1992003175A1 (fr)	1990-08-11	1992-03-05	Fisons Plc	Dispositif d'inhalation
DE4027391A1 (de)	1990-08-30	1992-03-12	Boehringer Ingelheim Kg	Treibgasfreies inhalationsgeraet
EP0640354B1 (fr)	1990-09-26	2001-12-05	Pharmachemie B.V.	Inhalateur pour poudres à tourbillon
GB9026025D0 (en)	1990-11-29	1991-01-16	Boehringer Ingelheim Kg	Inhalation device
AU650953B2 (en)	1991-03-21	1994-07-07	Novartis Ag	Inhaler
DE4239402A1 (de)	1992-11-24	1994-05-26	Bayer Ag	Pulverinhalator
MY115140A (en)	1992-12-18	2003-04-30	Schering Corp	Inhaler for powdered medications
BR9604977A (pt)	1995-04-14	1998-06-09	Glaxo Wellcome Inc	Inalador de dose medida sistema inalador de dose medida e uso do mesmo
HU220227B (hu)	1995-06-21	2001-11-28	Asta Medica A.G.	Gyógyszerporos patron integrált adagolószerkezettel és inhalálókészülék poralakú gyógyszerekhez
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
DE19536902A1 (de)	1995-10-04	1997-04-10	Boehringer Ingelheim Int	Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
WO2000035296A1 (fr)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Liberation amelioree d'agents medicamenteux actifs par un enrobage de chewing-gum
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
WO2001081346A2 (fr)	2000-04-25	2001-11-01	Icos Corporation	Inhibiteurs de la phosphatidyl-inositol 3-kinase delta humaine
DE10129703A1 (de)	2001-06-22	2003-01-02	Sofotec Gmbh & Co Kg	Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
ES2195785B1 (es)	2002-05-16	2005-03-16	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
TW200407143A (en)	2002-05-21	2004-05-16	Bristol Myers Squibb Co	Pyrrolotriazinone compounds and their use to treat diseases
ES2211344B1 (es)	2002-12-26	2005-10-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
WO2005016348A1 (fr)	2003-08-14	2005-02-24	Icos Corporation	Methodes d'inhibition de reponses immunes stimulees par un facteur endogene
ES2232306B1 (es)	2003-11-10	2006-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
EP1685124A1 (fr)	2003-11-10	2006-08-02	MERCK SHARP & DOHME LTD.	Utilisation d'heterocycles amines a six elements contenant de l'azote substitues comme antagonistes du recepteur vanilloide de type 1 pour le traitement de la douleur
ES2251866B1 (es)	2004-06-18	2007-06-16	Laboratorios Almirall S.A.	Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es)	2004-06-21	2007-06-16	Laboratorios Almirall S.A.	Nuevos derivados de piridazin-3(2h)-ona.
SI1616592T1 (sl)	2004-07-16	2011-03-31	Almirall Sa	Inhalator za uporabo farmacevtskih snovi v prahu in vloĹľek za prah za uporabo s tem inhalatorjem
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
WO2007023186A1 (fr) *	2005-08-26	2007-03-01	Laboratoires Serono S.A.	Derive de pyrazine et leur utilisation en tant qu'inhibiteurs de pi3k
ES2296516B1 (es)	2006-04-27	2009-04-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es)	2006-10-20	2009-06-12	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2319596B1 (es)	2006-12-22	2010-02-08	Laboratorios Almirall S.A.	Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
ES2306595B1 (es)	2007-02-09	2009-09-11	Laboratorios Almirall S.A.	Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY31272A1 (es)	2007-08-10	2009-01-30	Almirall Lab	Nuevos derivados de ácido azabifenilaminobenzoico
ES2320961B1 (es)	2007-11-28	2010-03-17	Laboratorios Almirall, S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2135610A1 (fr)	2008-06-20	2009-12-23	Laboratorios Almirall, S.A.	Combinaison comportant des inhibiteurs DHODH et de la méthotrexate
EP2196465A1 (fr)	2008-12-15	2010-06-16	Almirall, S.A.	Dérivés de (3-oxo)pyridazin-4-ylurée comme inhibiteurs de PDE4
UY32297A (es)	2008-12-22	2010-05-31	Almirall Sa	Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2210615A1 (fr)	2009-01-21	2010-07-28	Almirall, S.A.	Combinaisons comportant des inhibiteurs DHODH et de la méthotrexate
JP2012521994A (ja) *	2009-03-24	2012-09-20	ギリアードカリストガエルエルシー	２−プリニル−３−トリル−キナゾリノン誘導体のアトロプ異性体および使用方法
JP2012531435A (ja)	2009-06-25	2012-12-10	アムジエン・インコーポレーテツド	ＰＩ３Ｋ阻害剤としての４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン誘導体
WO2011058109A1 (fr)	2009-11-12	2011-05-19	Ucb Pharma S.A.	Dérivés de pyrrole et d'imidazole bicycliques condensés en tant qu'inhibiteurs de kinase
EP2518070A1 (fr)	2011-04-29	2012-10-31	Almirall, S.A.	Dérivés de pyrrolotriazinon en tant qu'inhibiteurs PI3K
WO2014015523A1 (fr)	2012-07-27	2014-01-30	Hutchison Medipharma Limited	Nouveaux composés hétéroaryliques et hétérocycliques et compositions et procédés s'y rapportant

2011
- 2011-04-29 EP EP11382124A patent/EP2518070A1/fr not_active Withdrawn
2012
- 2012-04-20 TW TW101114160A patent/TWI535720B/zh not_active IP Right Cessation
- 2012-04-25 TW TW101114743A patent/TW201242967A/zh unknown
- 2012-04-26 RS RS20150627A patent/RS54270B1/en unknown
- 2012-04-26 CN CN201280032781.1A patent/CN103649089B/zh not_active Expired - Fee Related
- 2012-04-26 PL PL12717685T patent/PL2702061T3/pl unknown
- 2012-04-26 SG SG2013074257A patent/SG194084A1/en unknown
- 2012-04-26 JP JP2014506869A patent/JP5903160B2/ja not_active Expired - Fee Related
- 2012-04-26 EP EP12717685.7A patent/EP2702061B9/fr active Active
- 2012-04-26 AU AU2012247491A patent/AU2012247491B2/en not_active Ceased
- 2012-04-26 ES ES12717685.7T patent/ES2545853T3/es active Active
- 2012-04-26 KR KR1020137028410A patent/KR20140021622A/ko active IP Right Grant
- 2012-04-26 UA UAA201313706A patent/UA111197C2/uk unknown
- 2012-04-26 DK DK12717685.7T patent/DK2702061T3/en active
- 2012-04-26 PE PE2013002204A patent/PE20141193A1/es not_active Application Discontinuation
- 2012-04-26 PT PT127176857T patent/PT2702061E/pt unknown
- 2012-04-26 EA EA201301209A patent/EA024350B1/ru not_active IP Right Cessation
- 2012-04-26 HU HUE12717685A patent/HUE026041T2/en unknown
- 2012-04-26 US US14/114,541 patent/US9340547B2/en not_active Expired - Fee Related
- 2012-04-26 BR BR112013023876A patent/BR112013023876A2/pt not_active IP Right Cessation
- 2012-04-26 ME MEP-2015-170A patent/ME02210B/me unknown
- 2012-04-26 SI SI201230347T patent/SI2702061T1/sl unknown
- 2012-04-26 CA CA2826197A patent/CA2826197A1/fr not_active Abandoned
- 2012-04-26 MY MYPI2013702039A patent/MY171553A/en unknown
- 2012-04-26 WO PCT/EP2012/057671 patent/WO2012146666A1/fr active Application Filing
- 2012-04-26 MX MX2013011781A patent/MX336214B/es unknown
- 2012-04-27 AR ARP120101485A patent/AR086144A1/es unknown
- 2012-05-02 UY UY0001034051A patent/UY34051A/es unknown
2013
- 2013-07-24 ZA ZA2013/05612A patent/ZA201305612B/en unknown
- 2013-08-01 IL IL227764A patent/IL227764A/en not_active IP Right Cessation
- 2013-10-15 CO CO13244188A patent/CO6801747A2/es not_active Application Discontinuation
- 2013-10-23 CR CR20130543A patent/CR20130543A/es unknown
- 2013-10-24 CL CL2013003073A patent/CL2013003073A1/es unknown
- 2013-10-28 GT GT201300266A patent/GT201300266A/es unknown
2014
- 2014-09-03 HK HK14108933.7A patent/HK1195552A1/xx not_active IP Right Cessation
2015
- 2015-10-29 CY CY20151100967T patent/CY1116871T1/el unknown
- 2015-10-29 SM SM201500270T patent/SMT201500270B/it unknown
- 2015-10-29 HR HRP20151153TT patent/HRP20151153T1/hr unknown

Also Published As

Publication number	Publication date
RS54270B1 (en)	2016-02-29
JP5903160B2 (ja)	2016-04-13
JP2014515027A (ja)	2014-06-26
DK2702061T3 (en)	2015-11-09
TW201242967A (en)	2012-11-01
EA024350B1 (ru)	2016-09-30
US9340547B2 (en)	2016-05-17
TW201247674A (en)	2012-12-01
SG194084A1 (en)	2013-11-29
UY34051A (es)	2012-11-30
EP2702061B1 (fr)	2015-07-29
MX2013011781A (es)	2013-11-01
GT201300266A (es)	2015-04-06
US20140163033A1 (en)	2014-06-12
CY1116871T1 (el)	2017-04-05
IL227764A (en)	2016-07-31
CA2826197A1 (fr)	2012-11-01
EA201301209A1 (ru)	2014-04-30
ME02210B (me)	2016-02-20
TWI535720B (zh)	2016-06-01
IL227764A0 (en)	2013-09-30
CO6801747A2 (es)	2013-11-29
PE20141193A1 (es)	2014-09-03
PT2702061E (pt)	2015-10-26
EP2702061B9 (fr)	2016-02-24
HRP20151153T1 (hr)	2015-12-04
AR086144A1 (es)	2013-11-20
MX336214B (es)	2016-01-12
HK1195552A1 (en)	2014-11-14
CR20130543A (es)	2014-03-17
SI2702061T1 (sl)	2016-01-29
ZA201305612B (en)	2014-05-28
BR112013023876A2 (pt)	2016-12-13
UA111197C2 (uk)	2016-04-11
AU2012247491B2 (en)	2016-08-18
CL2013003073A1 (es)	2014-02-21
EP2702061A1 (fr)	2014-03-05
HUE026041T2 (en)	2016-05-30
AU2012247491A1 (en)	2013-08-15
CN103649089A (zh)	2014-03-19
PL2702061T3 (pl)	2016-01-29
SMT201500270B (it)	2016-01-08
WO2012146666A1 (fr)	2012-11-01
US20150099752A9 (en)	2015-04-09
MY171553A (en)	2019-10-18
NZ614082A (en)	2015-05-29
KR20140021622A (ko)	2014-02-20
CN103649089B (zh)	2016-06-29
EP2518070A1 (fr)	2012-10-31

Publication	Publication Date	Title
ES2545853T3 (es)	2015-09-16	Derivados de pirrolotriazinona como inhibidores de PI3K
JP7389856B2 (ja)	2023-11-30	Ｕｓｐ３０阻害剤としての１－シアノ－ピロリジン化合物
ES2850349T3 (es)	2021-08-27	Derivados de cianopirrolidina con actividad como inhibidores de USP30
CN108473502B (zh)	2022-04-26	用于治疗癌症的4,6二氢吡咯并[3,4-c]吡唑-5(1h)-腈衍生物
ES2935392T3 (es)	2023-03-06	Imidazopirrolopiridina como inhibidores de la familia de quinasas JAK
CN109311896B (zh)	2021-08-24	吡唑并嘧啶衍生物作为激酶抑制剂
JP5579351B1 (ja)	2014-08-27	インダゾール
ES2704024T3 (es)	2019-03-13	Moduladores P2X7
AU2006239929B2 (en)	2011-11-03	Dipeptidyl peptidase-IV inhibitors
US11427601B1 (en)	2022-08-30	Inhibitors of KEAP1-Nrf2 protein-protein interaction
CA3174837A1 (fr)	2021-10-21	Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides utilises comme inhibiteurs de la voie de l'inflammasome nlrp3
ES2714048T3 (es)	2019-05-24	Moduladores de P2X7
US20210147427A1 (en)	2021-05-20	Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
JP2023134444A (ja)	2023-09-27	ピペリジニル－３－（アリールオキシ）プロパンアミド及びプロパノエート
MX2010012492A (es)	2010-12-21	Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados de enfermedad mediados por fosfodiesterasa 4.
WO2021063404A1 (fr)	2021-04-08	Composé utilisé comme inhibiteur de pd-1/pd-l1 à petites molécules et application associée
CN109415365B (zh)	2022-08-09	卡巴培南化合物
RU2812959C2 (ru)	2024-02-06	Новое производное гетероароматического амида и содержащий его лекарственный препарат
RU2772909C2 (ru)	2022-05-27	Карбапенемовые соединения
WO2023110700A1 (fr)	2023-06-22	Dérivés de dihydrofuropyridine utilisés comme inhibiteurs de la rho-kinase
CN117083272A (zh)	2023-11-17	调节nlrp3的4-烷氧基-6-氧代-哒嗪衍生物
CN117545757A (zh)	2024-02-09	5-氧代-吡啶并[2,3-d]哒嗪-6(5H)-基乙酰胺